Genova Biotherapeutics, Inc.(fka GVBP)

[Deewar25]

this is what I received - the retraction came a day after I received this (I assumed scam, but acted like I didn't in initial email):

Dear Dave,



The News Release is misleading. A correction /retraction will be issued shortly.


Best regards,


Tor



--------------------------------------------------------------------------------

From: Dave --- [mailto:[e-mail]]
Sent: 18 September 2009 06:53
To: [e-mail]
Cc: [e-mail]
Subject: Collaboration deal with Genova



Hi there, as per:


http://finance.yahoo.com/news/GENova-gains-access-to-Big-prnews-130945904.html?x=0&.v=2


I was wondering how long the terms of the arrangement go for? Is this indefinite, or will you be renegotiating after certain time periods?


TIA

------------------------------------

This was Sykes exchange & discussion per his blog (I'll cut/paste so he doesn't get a bunch of click through hits!) People can say what they want about Sykes - he is generally nothing but a short seller that targets pump and dumps, but he doesn't make this stuff up - what he posts is 100% truthful.


Tim - I am the CEO of BBR. What you have seen is not the full story.
Genova has issued two press releases without the knowledge of BBR management - and there are no contracts and we have never been in dialogue with them In fact I did not know the company existed before early morning Thursday the 17th.
I have informed Genova that a clarification is needed because:
“You simply cannot state “that it has ceased the relationship with Bridge BioResearch PLC” because there never was a relationship”
…and just a few hours later:
Further to the below – for clarification:
Genova has issued two press releases without the knowledge of BBR management
For further you can call me on ******** – or email. I will share any information I have on these people – just look at the CEO´s CV. He seems to be recycled.

Aaron Whiteman – Chief Executive Officer Ridgeback Mining

Aaron Whiteman holds a Bachelors of Law Degree from Oxford University and an MBA from the London School of Economics. Most recently, he served as a Vice President of Reliance Entertainment, India’s largest entertainment company, responsible for operations, business development and expansion into the European, Middle Eastern, and African regions. Prior to that, from May 2002 through May 2007, Mr Whiteman was a Vice President of Business Development at Game Federation, where he was responsible for promotion of the company’s products to strategic telecom partners globally. During his tenure, he successfully secured licensing agreements and commercial alliances with telecom giants such as Vodafone, T-Mobile, France Telecom and AT&T along with entertainment companies like Disney, Electronic Arts, Vivendi. He has also held various executive, board, and advisory positions in the telecommunication industry.

Aaron Whiteman – Chief Executive Officer Genova

Mr. Aaron Whiteman holds a Bachelors of Law Degree from Oxford University and an MBA from the London School of Economics. Most recently, he served as a vice president of Reliance Biotech, an Indian medical research company, responsible for business development and expansion into the European, Middle Eastern, and African regions. Prior to that, from May 2002 through May 2007, Aaron Whiteman was a vice president of Viranative AB, where he was responsible for promotion of the company’s products to strategic partners in the Sub-Saharan region. During his tenure, he successfully secured licensing agreements and commercial alliances with pharmaceutical giants Pharmacia (Upjohn), Astra Zeneca, and Glaxo Smith Kline. He has also held various executive, board, and advisory positions in the telecommunications industry.

And check their web – “investors” – “Industry news”

Regards
Søren Stenderup
CEO
Bridge BioResearch PLC

And then just to make sure I was getting the story straight, one last email:

Hi Tim
From my point of view this is pretty simple.
Genova has used the name of Bridge BioResearch PLC and one of our employees without our knowledge and consent.
An unconditional retraction regarding this has now been issued – and a short statement appears on the Genova Homepage. I have however yesterday (when the above release come to my attention) pointed out to Aaron Whiteman of Genova that submission of a clarification is needed. Genova cannot claim “that it has ceased the relationship with Bridge BioResearch PLC” - simply because there never was a relationship” I am sure that Mr. Whiteman understands this.

Just for the record – the issued press release was never mailed to me for approval. I had dialogue through a Genova advisor/consultant late Friday - regarding a press release proposal.

This proposal I changed to match our requirements – and I believed that Genova would comply. Sadly this was not the case and we are therefore demanding the above clarification.